Abstract: A new cranberry variety distinguished by early mid-season ripening period, precocious cropping, high productivity, and moderate-to-high fruit anthocyanin development, as compared to the currently cultivated commercial varieties.

Abstract: A new cranberry variety distinguished by mid-season ripening, round to ovate fruit, high productivity, and moderate fruit anthocyanin development, as compared to the currently cultivated commercial varieties.

Abstract: A new cranberry variety distinguished by very early season ripening, with exceptional early and high fruit anthocyanin (TAcy), as compared to the currently cultivated commercial varieties, with high fruit quality, and very suitable for the fresh fruit market.

Abstract: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-?-xylopyranoside, quercetin-3-?-glucoside, quercetin-3-?-arabinopyranoside, 3?-methoxyquercetin-3-?-xylopyranoside, quercetin-3-O-(6?-p-coumaroyl)-?-galactoside, and quercetin-3-O-(6?-benzoyl)-?-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-?-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

Abstract: A new cranberry variety distinguished by significantly higher yields, higher anthocyanin content (red pigment), higher stolon vigor, and earlier flowering phenology.

Abstract: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-?-xylopyranoside, quercetin-3-?-glucoside, quercetin-3-?-arabinopyranoside, 3?-methoxyquercetin-3-?-xylopyranoside, quercetin-3-O-(6?-p-coumaroyl)-?-galactoside, and quercetin-3-O-(6?-benzoyl)-?-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-?-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

Abstract: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-?-xylopyranoside, quercetin-3-?-glucoside, quercetin-3-?-arabinopyranoside, 3?-methoxyquercetin-3-?-xylopyranoside, quercetin-3-O-(6?-p-coumaroyl)-?-galactoside, and quercetin-3-O-(6?-benzoyl)-?-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-?-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

Abstract: A new cranberry variety distinguished by significantly higher yields, higher anthocyanin (red pigment) content, and higher stolon vigor as compared to the currently cultivated commercial varieties.

Abstract: The present invention is directed to extracts of cranberries (Vaccinium macrocarpon) comprising either mixed flavonols that are substantially free of anthocyanins and proanthocyanidins or a purified cranberry flavonol compound, including myricetin-3-?-xylopyranoside, quercetin-3-?-glucoside, quercetin-3-?-arabinopyranoside, 3?-methoxyquercetin-3-?-xylopyranoside, quercetin-3-O-(6?-p-coumaroyl)-?-galactoside, and quercetin-3-O-(6?-benzoyl)-?-galactoside. The present invention also embodies the use of those extracts, as well as extracts comprising the cranberry flavonol compound quercetin-3-?-arabinofuranoside, for the treatment of inflammatory disorders. Pharmaceutical, food, dietary supplement, and cosmetic compositions utilizing the extracts or compounds of the present invention are also recited.

Abstract: The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

Abstract: The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

Abstract: The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

Abstract: The present invention is directed to isolation and identification of plant proanthocyanidin extracts and particular proanthocyanidin compounds for prevention and treatment of urinary tract infections caused by P-type Escherichia coli. These extracts can be obtained from any proanthocyanidin-containing plants, including plants of the families Ericaceae, Rosaceae, Pinaceae, Vitaceae and the like. Preferably the extracts are from cranberry plants (especially, Vaccinium macrocarpon) and other plants, particularly fruit and berry plants from the Vaccinium spp. The extracts and compounds are also provided as pharmaceutical compositions, food additives and food compositions, especially beverages, ground meat preparations and cranberry-containing food products. The invention also relates to methods of reducing pathogenicity of P-type E. coli in the digestive tracts of cattle and reducing P-type E. coli contamination in ground meat as well as methods of detecting P-type bacteria.

Abstract: A new cranberry variety distinguished by significantly higher yields, higher anthocyanin (red pigment) content, and higher stolon vigor as compared to the currently cultivated commercial varieties.

Abstract: A new cranberry variety distinguished by significantly higher yields, higher anthocyanin content (red pigment), lower titratable acidity, and larger fruit size. In addition, high TAcy values in September provide for an earlier harvest window for processed fruit, especially relative to ‘Stevens’ (unpatented), a primary commercial variety.

Abstract: A new cranberry variety distinguished by significantly higher yields, higher anthocyanin content (red pigment), higher stolon vigor, and earlier flowering phenology.

Abstract: A new cranberry variety distinguished by very early season ripening, with exceptional early and high fruit anthocyanin (TAcy), as compared to the currently cultivated commercial varieties, with high fruit quality, and very suitable for the fresh fruit market.

Abstract: A new cranberry variety distinguished by mid-season ripening, round to ovate fruit, high productivity, and moderate fruit anthocyanin development, as compared to the currently cultivated commercial varieties.

Abstract: A new cranberry variety distinguished by early mid-season ripening period, precocious cropping, high productivity, and moderate-to-high fruit anthocyanin development, as compared to the currently cultivated commercial varieties.

Abstract: A new cranberry variety distinguished by midseason ripening and high productivity, especially in peat soils and moderate oceanic climate. Fruit are moderate to large in size, with variable shape, from widely ovate to oblong to pyriform.